Comparative Pharmacology
Head-to-head clinical analysis: EFFIENT versus PLAVIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFFIENT versus PLAVIX.
EFFIENT vs PLAVIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prasugrel is a thienopyridine prodrug that irreversibly inhibits the P2Y12 receptor on platelets, reducing ADP-mediated platelet aggregation.
Clopidogrel is a prodrug that is converted to an active metabolite by CYP450 enzymes. The active metabolite selectively inhibits the P2Y12 component of ADP receptors on the platelet surface, which prevents ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Loading dose: 60 mg orally once. Maintenance: 10 mg orally once daily. In patients weighing <60 kg, maintenance dose is 5 mg orally once daily.
75 mg orally once daily, with or without food. For acute coronary syndrome, a loading dose of 300 mg (or 600 mg for PCI) is given followed by 75 mg daily.
None Documented
None Documented
The terminal elimination half-life of the active metabolite is about 7.6 hours (range 2-15 hours). Clinically, this supports once-daily dosing.
Clopidogrel parent: ~6 hours; active thiol metabolite: ~30 minutes; terminal half-life of inactive metabolite(s): ~8 hours. Clinically, platelet inhibition persists for 5–7 days due to irreversible P2Y12 receptor binding.
Approximately 68% of the dose is excreted in urine as inactive metabolites, and about 27% in feces.
Renal: ~50% as inactive metabolites; biliary/fecal: ~50% as inactive metabolites.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent